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Characterisation, in-vitro and in-vivo evaluation of valproic acid-loaded nanoemulsion 
for improved brain bioavailability 
ABSTRACT 
OBJECTIVE: This study was aimed to investigate the potential of formulated valproic acid-
encapsulated nanoemulsion (VANE) to improve the brain bioavailability of valproic acid 
(VPA). METHODS: Valproic acid-encapsulated nanoemulsions were formulated and 
physically characterised (osmolarity, viscosity, drug content, drug encapsulation efficiency). 
Further investigations were also conducted to estimate the drug release, cytotoxic profile, in-
vitro blood-brain barrier (BBB) permeability, pharmacokinetic parameter and the 
concentration of VPA and VANE in blood and brain. KEY FINDINGS: Physical 
characterisation confirmed that VANE was suitable for parenteral administration. 
Formulating VPA into nanoemulsion significantly reduced the cytotoxicity of VPA. In-vitro 
drug permeation suggested that VANEs crossed the BBB as freely as VPA. Pharmacokinetic 
parameters of VANE-treated rats in plasma and brain showed F3 VANE had a remarkable 
improvement in AUC, prolongation of half-life and reduction in clearance compared to VPA. 
Given the same extent of in-vitro BBB permeation of VPA and VANE, the higher 
bioavailability of VANE in brain was believed to have due to higher concentration of VANE 
in blood. The brain bioavailability of VPA was improved by prolonging the half-life of VPA 
by encapsulating it within the nanoemulsion-T80. CONCLUSIONS: Nanoemulsion 
containing VPA has alleviated the cytotoxic effect of VPA and improved the plasma and 
brain bioavailability for parenteral delivery of VPA. 
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